Influence of preventive therapy with quinapril on IL-6 level in patients with chronic stable angina

Pharmacological Reports

Volumn 59, Issue 3, 2007, Pages 330-338

  Gibas, Magdalena ^a   Miszczak Śmiałek, Jolanta ^b   Madry, Edyta ^a   Głuszek, Jerzy ^a   Witmanowski, Henryk ^a   Piotrowski, Janusz ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Grunwaldzki Hospital   (Poland)

Author keywords

Angiotensin converting enzyme inhibitors; Coronary artery disease; Inflammation; Interleukin 6

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; NITRATE; PLACEBO; QUINAPRIL;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPOTHESIS; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STABLE ANGINA PECTORIS; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 34548134047     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bermudez EA, Rifai N, Buring JE, Manson JE, Ridker PM: Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol, 2002, 89, 1117-1119.
2. Biasucci LM, Vitelli A, Liuzzo G, Luigi M, Altamura S, Caligiuri G, Monaco C et al.: Elevated levels of interleukin-6 in unstable angina. Circulation, 1996, 94, 874-877.
3. Castell JV, Andus T, Kunz D, Heinrich PC: Interleukin 6: the major regulator of acute phase protein in man and rat. Ann NY Acad Sci, 1989, 557, 87-101.
4. Criqui MH, Golomb BA: Epidemiologic aspects of lipid abnormalities. Am J Med, 1998, 105, 48S-57S.
5. Chudek J, Wiecek A: Adipose tissue, inflammation and endothelial dysfunction. Pharmacol Rep, 2006, 58, Suppl, 81-88.
6. de Maat MPM, Kluft C: The association between inflammation markers, coronary artery disease and smoking. Vasc Pharmacol, 2002, 39, 137-139.
7. Du Clos TW: Function of C-reactive protein. Ann Med, 2000, 32, 274-278.
8. Fox KM: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 2003, 362, 782-788.
9. Funakoshi Y, Ichiki T, Ito K, Takeshita A: Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells. Hypertension, 1999, 34, 118-125.
10. Griendling KK, Ushio-Fukai M, Lassegue B, Alexander RW: Angiotensin II signaling in vascular smooth muscle. Hypertension, 1997, 29, 366-373.
11. Han Y, Runge MS, Brasier AR: Angiotensin II induces IL-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-κB transcription factors. Circ Res, 1999, 84, 695-703.
12. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P: Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation, 1999, 100, 793-798.
13. Ito T, Ikeda U, Shimpo M, Ohki R, Takahashi M, Yamamoto K, Shimada K: HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells. Cardiovasc Drugs Ther, 2002, 16, 121-126.
14. Keidar S, Heinrich R, Kaplan M, Hayek T, Aviram M: Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for IL-6. Arterioscler Thromb Vasc Biol, 2001, 21, 1464-1469.
15. Kharbanda RK, Walton B, Allen M, Klein N, Hingorani AD, MacAllister RJ, Vallance P: Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation, 2002, 105, 2600-2604.
16. Kim S, Iwao H: Molecular and cellular mechanisms of angiotensin II mediated cardiovascular and renal diseases. Pharmacol Rev, 2000, 52, 11-34.
17. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation, 2002, 105, 1135-1143.
18. Miyao, Y, Yasue H, Ogawa H, Misumi I, Masuda T, Sakamoto T, Morita E: Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am J Heart, 1993, 126, 1299-1304.
19. Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A: Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol, 2001, 77, 247-253.
20. Phillips MI, Kagiyama S: Angiotensin II as a proinflammatory mediator. Curr Opin Investig Drugs, 2002, 3, 569-577.
21. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med, 1997, 336, 973-979.
22. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 2000, 342, 836-843.
23. Rosenson RS, Tangnay CC, Casey LC: Inhibition of proinflammatory cytokine production by pravastatin. Lancet, 1999, 353, 983-984.
24. Ross R: Mechanisms of disease: atherosclerosis: an inflammatory disease. N Engl J Med, 1999, 340, 115-126.
25. Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker GC, Kowey PR, Lamas GA et al.: Effects of captopril on ischemic events after myocardial infarction. Results of the survival and ventricular enlargement trial. SAVE Investigators. Circulation, 1994, 90, 1731-1738.
26. Schindler R, Dinarello CA, Koch KM. Angiotensin-converting-enzyme inhibitors suppress synthesis of tumor necrosis factor and interleukin-1 by human peripheral blood mononuclear cells. Cytokine, 1995, 7, 526-533.
27. Tappia PS, Troughton KL, Langley-Evans SC, Grimble RF: Cigarette smoking influences cytokine production and antioxidant defences. Clin Sci, 1995, 88, 485-489.
28. Yudkin JS, Kumari M, Humphries SE, Mohamed Ali V: Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis, 2000, 148, 209-214.
29. Yusuf S, Sleight P, Pogue J, Bosh J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study (HOPE) Investigators. N Engl J Med, 2000, 342, 145-153.
30. Zhao SP, Zhang DQ: Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits. Clin Chim Acta, 2003, 336, 103-108.